Showing results (31-40 of 38) with videos related to
Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 38 results.
Eclinicalmedicine|January 1, 2026
Efficiency and safety of sintilimab-based induction therapy in potentially resectable stage III non-small cell lung cancer (LungMate-009): an open-label, phase 2 trialTao Ge, Hongyi Zhang, Xinsheng Zhu, et al.Nature Communications|February 24, 2025
Anti-PD1 based precision induction therapy in unresectable stage III non-small cell lung cancer: a phase II umbrella clinical trialChengxiang Yi, Dongliang Bian, Jue Wang, et al.Nature Genetics|December 10, 2024
Multi-omic profiling highlights factors associated with resistance to immuno-chemotherapy in non-small-cell lung cancerYilv Yan, Dongqing Sun, Junjie Hu, et al.Cell Reports. Medicine|June 26, 2026
Multi-omics profiling unveils biological and clinical insights into pulmonary sarcomatoid carcinomaLiangdong Sun, Jue Wang, Yilv Yan, et al.BMC Medicine|December 29, 2022
Safety and effectiveness of neoadjuvant PD-1 inhibitor (toripalimab) plus chemotherapy in stage II-III NSCLC (LungMate 002): an open-label, single-arm, phase 2 trialXinsheng Zhu, Liangdong Sun, Nan Song, et al.Nature Communications|April 1, 2025
Neoadjuvant Aumolertinib for unresectable stage III EGFR-mutant non-small cell lung cancer: a single-arm phase II trialDongliang Bian, Shuyu Ji, Yue Liu, et al.Cell Discovery|November 25, 2025
Surgery after induced anti-PD-L1 therapy and chemotherapy for stage I‒III small-cell lung cancer: a phase 2 trial (LungMate-005)Fenghuan Sun, Lele Zhang, Liangdong Sun, et al.Signal Transduction and Targeted Therapy|June 13, 2024
Neoadjuvant camrelizumab (an anti-PD-1 antibody) plus chemotherapy or apatinib (a VEGFR-2 inhibitor) for initially unresectable stage II-III non-small-cell lung cancer: a multicentre, two-arm, phase 2 exploratory studyHaoran Xia, Han Zhang, Zheng Ruan, et al.Pageof 4